An increasingly complete compendium of recurrently mutated genes in myelodysplastic syndromes (MDS) has been defined, and the application of massively parallel sequencing to identify mutations in clinical practice now promises to improve the care of patients with this disease. More than 25 recurrent MDS-associated somatic mutations have been identified, involving biological pathways as diverse as chromatin remodeling and pre-mRNA splicing.
2

BACKGROUND:
The myelodysplastic syndromes (MDS) comprise a clinically and pathologically heterogeneous group of hematologic neoplasms, collectively characterized by clonal hematopoiesis, aberrant myeloid differentiation, ineffective hematopoiesis leading to cytopenias, and a risk of progression to acute myeloid leukemia (AML)(1). The risk of developing MDS is increased both by exogenous factors, such as exposure to cytotoxic chemotherapy, radiation or benzene, and by inherited genetic predisposition, including that associated with congenital bone marrow failure disorders or several non-syndromic familial disorders that predispose to MDS/AML.
The diagnosis of MDS is based on persistent cytopenias in association with characteristic dysplastic findings in the peripheral blood (PB) and bone marrow (BM), excess blasts, or a cytogenetic or molecular marker proving clonality, as well as exclusion of other diseases (2) . The 2008 World Health Organization (WHO) classification of hematologic neoplasms includes several MDS subtypes, defined by the proportion of blood and marrow blasts, the presence or absence of monocytosis or ring sideroblasts, cytogenetic findings, and the specific cell lineages involved by dysplasia (3) . Despite the clinical utility of WHO subgrouping, significant heterogeneity in phenotype and outcome persists within WHO-defined MDS categories (4, 5) and there are also challenging cases where a diagnosis of MDS is possible but minimal diagnostic criteria are not met (6) .
Because of wide variation in the clinical course of MDS, treatment algorithms for MDS rely heavily on accurate prognostic stratification. Investigators have made multiple attempts to incorporate clinical and pathological information into risk models for patients with MDS, in order to guide treatment recommendations. The
International Prognostic Scoring System (IPSS), published in 1997, was developed to assess prognosis of untreated adult patients with primary MDS (7) .
Research. 
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Since then, a number of other classification and prognostic scoring schemata have been developed with the goal of more accurately identifying disease subtypes with similar outcomes and risks of evolution to AML (8) (9) (10) (11) (12) . Most recently, the revised IPSS (IPSS-R) defines five major prognostic categories based on five cytogenetic risk subgroups (including a broader range of karyotypic abnormalities than the original IPSS), BM blast percentage, and number and severity of cytopenias(4).
Clinicians currently tailor therapeutic recommendations to each patient's situation, depending on the predicted risk of disease and the patient's age, comorbid conditions, and functional status (13) . Integration of somatic mutation assays into MDS diagnosis, risk stratification, and prediction of therapeutic response, has the potential to greatly improve treatment outcomes for this patient population. In addition, better understanding of the biologic basis of MDS will aid in the design of targeted, rationally designed novel therapies.
ON THE HORIZON
Identification of Recurrent Somatic Mutations in MDS
Genetic lesions that drive the phenotype of MDS contribute to enhanced or acquired self-renewal and impaired differentiation. Additional abnormalities in the BM microenvironment and in the epigenetic state of malignant cells may independently contribute to disease pathogenesis (14, 15) . The compendium of genes with recurrent somatic mutations in MDS has grown dramatically over the last few years with the application of single nucleotide polymorphism (SNP) arrays, whole exome sequencing, and whole genome sequencing.
The genes mutated in MDS can be grouped into several categories: (1) transcription factors (e.g., TP53, RUNX1, ETV6) (16) (17) (18) , (2) Table 2 ).
The phenotypic heterogeneity within MDS -as highlighted by the presence of variable number and severity of cytopenias, blast proportion, rate of progression to AML, response to treatment, and overall survival (OS) -is likely driven, to a great extent, by the specific pattern of these genetic changes and their interaction with therapeutic choices. Since many patients have several detectable genetic changes, it will be important to understand the interaction of these mutations with each other, as well as the impact of varying allele burden (i.e. degree of clonality) and its influence on the clinical phenotype. 
Decoding the Epigenetic Landscape of MDS
Moving Toward Improved Diagnostics
The diagnostic evaluation of MDS has not changed significantly in the last 30 years and still relies on PB findings, morphologic evaluation and G-banded metaphase karyotyping of a BM sample(34). However, morphologic diagnosis of MDS remains challenging and often lacks inter-observer concurrence, with a 12% discordance rate among different pathologists with respect to diagnosing dysplasia, and even greater discrepancy when assigning a specific MDS subtype (35) (36) (37) . Uncertainty about MDS diagnosis impairs prognostic assessment and therapeutic decision making. 
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Lastly, it is possible that a broad range of clinicians, including primary care providers, will eventually be able to evaluate their patients with new-onset cytopenias via PB testing for the presence of MDS-defining mutations, once a few common non-clonal causes of cytopenias such as nutritional deficiencies have been excluded. Having non-invasive option for diagnosis of MDS would be predicted to lower the threshold for testing and result in earlier identification of cases. Furthermore, although the initial diagnostic confirmation would most likely still involve a BM biopsy with a karyotype analysis even in patients with documented somatic mutations in their PB, serial repeat BM biopsies could become less critical for monitoring treatment response and disease progression.
Moving Toward Improved Classification and Prognostication
Multiple classification and prognostic scoring systems have been developed to identify MDS subtypes or risk groups with similar outcomes, as discussed above (4, (7) (8) (9) (10) (11) (12) . These schemes are based on morphology, clinical variables such as cytopenias, and cytogenetics. Somatic mutations are fundamental determinants of MDS pathophysiology, but are not part of any of the existing risk stratification systems.
Future classification and prognostic scoring systems may incorporate somatic mutations into existing models. Alternatively, new classification schemes and prognostic scoring systems may be developed that are fundamentally based on molecular abnormalities. If all mutations can be detected in PB by deep sequencing, it is possible that MDS could be diagnosed, classified and followed over time using PB without the need for repeat BM biopsies (Figure 1) . (47) . In another retrospective study of 86 patients with MDS treated with azacitidine, the presence of a TET2 mutation was associated with an 82% response rate, compared to a 45% response rate in TET2 wild-type patients (48) . Additional studies designed to identify genetic predictors of response to different treatment modalities, such as hypomethylating agents or stem cell transplantation, will be critical for tailoring appropriate therapy to each patient and minimizing toxicities from treatments with a low likelihood of therapeutic benefit.
Identification of Predictors of Response to Treatment
Monitoring Response to Treatment
The ability to monitor treatment response via a non-invasive test would provide critical information to clinicians about ongoing therapeutic response and the 
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approach to patients with MDS, from diagnosis, prognosis and risk stratification, and treatment. We envision that assays for clinically relevant somatic mutations will soon become part of routine evaluation of patients in clinic (Figure 1 ) as well as provide fertile ground for the development of novel therapeutic strategies for the treatment of MDS.
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